BioAdaptives, Inc.

BDPT

US09072U1079

Food Processing

Market Closed - OTC Markets Other stock markets 03:57:02 2024-05-31 pm EDT			5-day change	1st Jan Change
0.0006 ^USD	-.--%		+20.00%	+20.00%

May. 30	Bioadaptives, Inc. Welcomes Gimhana Dissanayake to its Board of Directors	CI
May. 22	BioAdaptives, Inc. Announces CEO Changes	CI

BioAdaptives, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 17, 2024 at 04:10 pm EDT

BioAdaptives, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 0.011994 million compared to USD 0.003376 million a year ago. Net loss was USD 0.306707 million compared to USD 0.287187 million a year ago.

Latest news about BioAdaptives, Inc.

Bioadaptives, Inc. Welcomes Gimhana Dissanayake to its Board of Directors	May. 30	CI
BioAdaptives, Inc. Announces CEO Changes	May. 22	CI
BioAdaptives, Inc. Announces Management Changes	May. 22	CI
BioAdaptives, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 17	CI
BioAdaptives, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Bioadaptives, Inc. Announces Naturacomplete?, an All-In-One Supplement to Optimize Its Ai-Based FYO Obesity Management System	Feb. 22	CI
BioAdaptives Announces Signing of a New Distributor?s Agreement for AI Body Composition Measuring App and New Weight Management System	Jan. 17	CI
BioAdaptives Inc. Announces the Development of PROTEINnMORETM	Dec. 14	CI
BioAdaptives Announces the Development of VeganHepPlusTM Liver Supplement Formula	Nov. 16	CI
BioAdaptives, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
BioAdaptives, Inc. Highlights Continued Success of Popular LUNG ARMOR System as US Enters Flu Season	Nov. 09	CI
BioAdaptives, Inc. Announces Nationwide Launch of Lung Fortress Natural Supplement	23-10-10	CI
BioAdaptives, Inc. Commences Development of A New Supplement for Women?S Health	23-10-05	CI
BioAdaptives, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
BioAdaptives, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
BioAdaptives, Inc. Announces the Appointment of David Allen to its Board of Directors	23-04-13	CI
BioAdaptives, Inc. Signs Non-Exclusive Marketing Agreement with World Wellness, LLC	23-04-06	CI
BioAdaptives, Inc. Announces the Appointment of Dr. Yaguang Liu to its Board of Directors	23-04-05	CI
BioAdaptives, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
BioAdaptives, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
BioAdaptives Signs Non-Exclusive License with LY Research to Market Patented Product for Glucose Management	23-03-28	CI
BioAdaptives, Inc. Establishes A Wholesale Division to Expand Marketing Presence in USD 151.9 Billion Global Dietary Supplement Market	22-12-08	CI
BioAdaptives, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
BioAdaptives, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Bioadaptives Launches MindnMemory Nootropic Mental Focus, Clarity, Concentration	22-07-28	CI

Chart BioAdaptives, Inc.

Duration

Period

More charts

Company Profile

BioAdaptives, Inc. manufactures and distributes natural plant and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. Its product line for humans includes PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore. It also markets the Lung Flute and PrimiLungs products in its Lung Armor packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the device. Its animal products include an Equine All-in-One and Equine All-In-One Plus formulation, which it markets to trainers, horse owners and boarding stables, and a Canine All-in-One.

Sector

Food Processing

More about the company

Income Statement Evolution

More financial data

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
BIOADAPTIVES, INC.	+20.00%	739K
ZHEJIANG NHU COMPANY LTD.	+11.85%	8.05B
BELLRING BRANDS, INC.	+4.94%	7.59B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+2.63%	6.07B
THE SIMPLY GOOD FOODS COMPANY	-2.80%	3.85B
BYHEALTH CO., LTD	-11.22%	3.55B
XIAMEN KINGDOMWAY GROUP COMPANY	-7.04%	1.28B
HERBALIFE LTD.	-32.50%	1.03B
SIRIO PHARMA CO., LTD.	+12.52%	971M
JAMIESON WELLNESS INC.	-15.69%	813M